Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing

Author:

Mansukhani Sonia1,Barber Louise J1,Kleftogiannis Dimitrios1,Moorcraft Sing Yu2,Davidson Michael2,Woolston Andrew1,Proszek Paula Zuzanna3,Griffiths Beatrice1,Fenwick Kerry4,Herman Bram5,Matthews Nik4,O'Leary Ben6,Hulkki Sanna3,Gonzalez De Castro David7,Patel Anisha8,Wotherspoon Andrew9,Okachi Aleruchi2,Rana Isma2,Begum Ruwaida2,Davies Matthew N1,Powles Thomas10,von Loga Katharina1,Hubank Michael3,Turner Nick611,Watkins David2,Chau Ian2,Cunningham David2,Lise Stefano1,Starling Naureen2,Gerlinger Marco12

Affiliation:

1. Centre for Evolution and Cancer, Division of Molecular Pathology, The Institute of Cancer Research, London, UK

2. Gastrointestinal Cancer Unit, The Royal Marsden NHS Foundation Trust, London and Sutton, UK

3. Centre for Molecular Pathology, The Royal Marsden NHS Foundation Trust, Sutton, UK

4. Tumour Profiling Unit, The Institute of Cancer Research, London, UK

5. Diagnostics and Genomics Group, Agilent Technologies Inc., Santa Clara, CA

6. Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK

7. Centre for Cancer Research and Cell Biology, Belfast, UK

8. Department for Radiology, The Royal Marsden NHS Foundation Trust, London and Sutton, UK

9. Department of Histopathology, The Royal Marsden NHS Foundation Trust, London and Sutton, UK

10. Barts Cancer Institute, Queen Mary University of London, London, UK

11. Breast Cancer Unit, The Royal Marsden NHS Foundation Trust, London and Sutton, UK

Abstract

Abstract BACKGROUND Circulating free DNA sequencing (cfDNA-Seq) can portray cancer genome landscapes, but highly sensitive and specific technologies are necessary to accurately detect mutations with often low variant frequencies. METHODS We developed a customizable hybrid-capture cfDNA-Seq technology using off-the-shelf molecular barcodes and a novel duplex DNA molecule identification tool for enhanced error correction. RESULTS Modeling based on cfDNA yields from 58 patients showed that this technology, requiring 25 ng of cfDNA, could be applied to >95% of patients with metastatic colorectal cancer (mCRC). cfDNA-Seq of a 32-gene, 163.3-kbp target region detected 100% of single-nucleotide variants, with 0.15% variant frequency in spike-in experiments. Molecular barcode error correction reduced false-positive mutation calls by 97.5%. In 28 consecutively analyzed patients with mCRC, 80 out of 91 mutations previously detected by tumor tissue sequencing were called in the cfDNA. Call rates were similar for point mutations and indels. cfDNA-Seq identified typical mCRC driver mutations in patients in whom biopsy sequencing had failed or did not include key mCRC driver genes. Mutations only called in cfDNA but undetectable in matched biopsies included a subclonal resistance driver mutation to anti-EGFR antibodies in KRAS, parallel evolution of multiple PIK3CA mutations in 2 cases, and TP53 mutations originating from clonal hematopoiesis. Furthermore, cfDNA-Seq off-target read analysis allowed simultaneous genome-wide copy number profile reconstruction in 20 of 28 cases. Copy number profiles were validated by low-coverage whole-genome sequencing. CONCLUSIONS This error-corrected, ultradeep cfDNA-Seq technology with a customizable target region and publicly available bioinformatics tools enables broad insights into cancer genomes and evolution. ClinicalTrials.gov Identifier NCT02112357

Funder

Institute of Cancer Research

Publisher

Oxford University Press (OUP)

Subject

Biochemistry (medical),Clinical Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3